Oroperidys (Domperidone)

Domperidone, the active ingredient in Oroperidys, is a dopamine‑receptor antagonist presented as an oral tablet for gastrointestinal use. It helps relieve nausea, vomiting and improves gastric motility in adults.

GNH USA supplies Oroperidys as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Domperidone acts on the dopaminergic pathways that regulate gastrointestinal motility and the vomiting centre.

Nausea and vomiting: reduces symptoms associated with medication, chemotherapy or postoperative states. Gastroparesis: enhances gastric emptying in patients with delayed stomach emptying. Functional dyspepsia: alleviates upper abdominal discomfort and bloating.

Domperidone may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Dry mouth: reduced salivary flow causing throat discomfort. - Headache: mild to moderate pain often transient. - Abdominal cramps: discomfort in the stomach area. - Dizziness: sensation of light‑headedness. - Diarrhoea: loose stools occurring shortly after dosing. - Constipation: reduced bowel movements.

Serious or Rare Side Effects: - Cardiac arrhythmia (QT prolongation): may lead to palpitations or fainting. - Severe allergic reaction: rash, swelling, or difficulty breathing. - Extrapyramidal symptoms: rare movement disorders such as tremor. - Hyperprolactinaemia: elevated prolactin causing galactorrhoea. - Hepatic dysfunction: abnormal liver enzymes. - Neuroleptic malignant syndrome: extremely rare, characterised by fever and muscle rigidity.

Before prescribing Domperidone, clinicians should evaluate patient‑specific risk factors and monitor for adverse events.

Assess cardiac risk: review history of arrhythmia or prolonged QT interval. Monitor QT interval: obtain baseline ECG in high‑risk patients. Avoid in hepatic impairment: dose adjustment may be required. Use caution in the elderly: increased susceptibility to side effects. Review concomitant QT‑prolonging drugs: consider alternatives or enhanced monitoring. Store at room temperature: keep in the original pack, protect from moisture.

Domperidone can interact with several medicines, altering its safety profile or efficacy.

Major Interactions (Avoid): - Ketoconazole: potent CYP3A4 inhibition increases domperidone levels. - Erythromycin or clarithromycin: raise plasma concentrations, heightening cardiac risk. - Other QT‑prolonging agents (e.g., quinidine, sotalol): additive effect on cardiac repolarisation. - Cisapride: combined dopamine antagonism may cause severe arrhythmias.

Moderate Interactions (Monitor Closely): - Fluconazole: moderate CYP3A4 inhibition may require ECG monitoring. - Anticholinergic drugs: may blunt pro‑kinetic effect. - Antacids containing aluminium or magnesium: can reduce domperidone absorption if taken simultaneously.